World Immunotherapy Congress - Agenda Day 2

 

World Immunotherapy Congress 2018, Day 2

08:00 Registration Opens

08:50 Conference doors open

Combination therapies

08:55

Chair's opening remarks

09:40

Title TBC

10:00

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

10:20 Networking refreshment break

Oncology – immunotherapy for solid tumours

Manufacture, logistics and supply chain

Chaired by TBC

Chaired by TBC

Immunotherapy - Immunotherapy for solid tumours
11:25

Microenvironmental links between adipose tissue and cancer

  • Excess adiposity in obesity has been associated with increases risk of cancer development as well as negative prognosis in several cancer types
  • Preclinical models of cancer and obesity will be presented
  • Contribution of cellular constituents of the adipose tissue to tumour development will be discussed
Immunotherapy - Manufacture, logistics and supply chain
11:25

Closed systems for CAR T-cell production

  • Closed non-magnetic selection technology (automated T-CATCH)
  • Soluble reversible activation technology (Expamer)
  • Short production process (Nex-T)
Immunotherapy - Immunotherapy for solid tumours
11:45

T-SIGn viruses: systemic delivery of localised combination immuno-gene therapy within the tumour microenvironment

  • T-SIGn platform: transgene-bearing genetically modified variants of enadenotucirev, an oncolytic chimeric group B adenovirus with clinical data demonstrating virus delivery to tumours following systemic dosing
  • Up to 4 different transgenes have been encoded in a single virus, enabling the design of candidates expressing combinations of biological agents for targeted immunotherapy
  • Local production of therapeutic combinations by tumour cells infected with the T-SIGn virus enables high local production for increased activity while minimizing systemic exposure for improved safety
Immunotherapy - Manufacture, logistics and supply chain
11:45

Cell therapy supply chain management, logistics and scale out

  • Shipper suitability, features and options
  • Maintaining chain of custody for starting material and product
  • Logistics reliability and options
  • Supply chain sustainability and scale-out
Immunotherapy - Immunotherapy for solid tumours
12:05

T cell redirecting antibodies based on Glenmark’s BEAT® platform

  • Presentation of the T cell redirecting BEAT antibodies currently in development: GBR 1302, GBR 1342 and GBR 1372
  • Rationale for the architecture based on the target tumor antigen
  • Preclinical data highlighting the mechanism of action, and potency, in relation with standard of care
  • Translational data on primary cancer samples
Immunotherapy - Manufacture, logistics and supply chain
12:05

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Immunotherapy - Immunotherapy for solid tumours
12:25

T3 Pharma’s versatile bacterial cancer therapy

  • How to target bacteria to solid tumours
  • How to enable bacteria to fight solid tumours
  • Use of such bacteria in immunotherapy
Immunotherapy - Manufacture, logistics and supply chain
12:25

Cell therapy manufacture

Immunotherapy - Immunotherapy for solid tumours
12:45

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Immunotherapy - Manufacture, logistics and supply chain
12:45

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

Networking lunch

Oncology – combination therapy

Manufacture, logistics and supply chain

Chaired by TBC

Chaired by TBC

Immunotherapy - Manufacture, logistics and supply chain
14:35

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Immunotherapy - Combination therapy
14:55

Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab

  • Understand the rationale for combining an APC activator (LAG-3lg or “efti”) with an immune checkpoint inhibitor (anti-PD-1 pembrolizumab)
  • Pharmacodynamic effects of efti (6 or 30 mg s.c.) in patients
  • Highlighting in vitro and in vivo preclinical data along with emerging clinical data
Immunotherapy - Manufacture, logistics and supply chain
14:55

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Immunotherapy - Combination therapy
15:15

IgA as novel antibody format for lymphoma and neuroblastoma is enhanced by myeloid checkpoint inhibitors

  • IgA recruits neutrophils as effector cells for treatment of cancer
  • Preclinical evidence for mode of action of IgA
  • Adverse effect for neuroblastoma treatment is eliminated with IgA
  • Blocking CD47/SIRPα axis strongly enhances IgA effects
Immunotherapy - Manufacture, logistics and supply chain
15:15

Workshop: Logistics and supply chain management for cell therapy

  • Developing manufacturing that produces a high-quality product
  • Scalable to meet changing demands of cell therapies
  • Keeping reasonable cost of goods
  • Fully characterising cell therapy products
Immunotherapy - Combination therapy
15:35

Title to be announced

Oliver Hill, Vice President Of Molecular Biology, Apogenix Ag

15:55 Networking Break

Oncology - neoantigens

Immunotherapy for non-oncology

Chaired by TBC

Chaired by TBC

Immunotherapy - Neoantigens
17:00

Driving high T-cell titers to neoantigens in tumours – harnessing immunogenic viral vectors with immune check point modulators

  • DNA damage may cause mutations in tumours that can generate new antigens, known as tumour-specific neo-antigens (TSNAs)
  • Accurate prediction of TSNAs is key to generate potent TSNA specific vaccine approaches
  • Viral vector based vaccine platforms have shown to induce hi-titer, polyfunctional and durable CD4+ and CD8+ T-cell responses in humans
  • The personalized vaccine is delivered in combination with immune checkpoint blockade, to keep TSNA-induced T-cells active in the immunosuppressive tumour microenvironment
Immunotherapy - Immunotherapy for non-oncology
17:00

Targeting combined treatments to arthritic joints by antibody-specific to damaged cartilage: a safer therapy platform for rheumatoid arthritis

  • There are 40% of patients with rheumatoid arthritis that do not respond to treatments
  • A major issue with systemic treatment due to side effects
  • We developed a platform that can address these unmet needs by:
    • Targeting treatments to the disease tissue
    • Utilize the efficacy of combined biologics which could otherwise lead to major advert effects if administered systemically
Immunotherapy - Neoantigens
17:20

ACE ImmunoID platform for the next generation of cancer immunotherapies and combination clinical trials

  • Current limitations with conventional next generation sequencing assays and Personalis’ solutions to overcome these challenges with its Accuracy and Content Enhanced technology
  • Key considerations for designing rapid, patient-centric processes for neoantigen-based cancer vaccine clinical trials and combination therapies
  • A case study demonstrating the platform’s applicability in identifying multidimensional biomarkers for cancer immunotherapy
Immunotherapy - Neoantigens
17:40

Development of a cost-effective personalized cancer neoantigen vaccines inducing a unique CD8-dominated T cell response

  • Potentiating vaccines by attracting, activating and delivering antigens to antigen presenting cells
  • Targeting results in a unique CD8-dominated T cell response.
  • DNA vaccine format allows a rapid, cost-effective and robust manufacturing process viable for manufacturing patient-specific vaccines on demand
  • A clinical study using targeted Vaccibody neoepitope DNA vaccines in multiple advanced cancer indications is ongoing
Immunotherapy - Immunotherapy for non-oncology
17:40

Proteomics crashes at the intersection of autoimmunity and cell biology

  • Review novel protein modifications that trigger autoimmune responses and pathology
  • Discuss proteins modifications that also alter cell biology and metabolism
  • Protein biomarkers as indicators of disease progression and therapeutic strategies
Immunotherapy - Neoantigens
18:00

Individualized therapeutic cancer vaccines – How to select for immunogenic neoantigens?

  • Selecting the right tumour specific antigens - the key for successful therapeutic T cell cancer vaccines
  • Bypassing prediction - identification of tumour specific T cell antigens by a functional readout
  • Vaccination with common tumour antigens - decoding the “Mutanome” presented on HLAs
Immunotherapy - Immunotherapy for non-oncology
18:00

Combinatorial therapeutic HIV-1 vaccines: Time for immune checkpoint inhibitors

  • Talk will focus on HIV-1 infected and treated patients who received therapeutic vaccination
  • Discuss the current work on how to improve therapeutic vaccination using immune checkpoint inhibitors

18:20 Poster presentation and networking drinks

last published: 14/Sep/18 10:45 GMT

 

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates